Hypoxia-associated factor expression in low-grade and anaplastic gliomas: a marker of poor outcome.

Somatic mutations in isocitrate dehydrogenase (IDH) genes have recently been identified in a large proportion of glial tumors of the CNS and reported to be a strong prognostic factor in gliomas whatever the tumor grade. Few data are available in the literature regarding the relationship between IDH mutations and HIF expression in low-grade gliomas (LGGs), especially in a recently described aggressive molecular subtype: "triple negative" (IDH non mutated, 1p 19q non codeleted, p53 expression negative) gliomas. We analyzed clinical, radiological and molecular features of a series of 31 grade II/III gliomas. p53 expression, 1p19q deletion and IDH mutation status were provided for all tumors. Also HIF (hypoxia inducible factor)-1α, HIF-2α, HAF, Sox2 (SRY(Sex determining region Y)-box2) and OCT (octamer binding factor) 3/4 expressions were analyzed. We found positive HIF-2α staining in 38.7% of cases which was uncorrelated to HIF-1α expression or IDH1/2 mutation status. However, HIF-2α staining was significantly associated with HAF expression, a stem-like cell marker, in the whole population. HAF expression was present in 74.2% of cases and significantly correlated to Sox2 expression. Furthermore, HAF expression was significantly associated with the "triple negative" glioma phenotype. We provide here first evidence that HAF, a stem-like cell marker, expression is highly correlated to the triple negative aggressive LGG/AG molecular phenotype suggesting that these tumours might arise from cells of different origin.

[1]  Gabriele Schackert,et al.  Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups , 2015, Acta Neuropathologica.

[2]  S. Weiss,et al.  Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. , 1992, Science.

[3]  L. Mariani,et al.  Alterations in the RB1 Pathway in Low‐grade Diffuse Gliomas Lacking Common Genetic Alterations , 2011, Brain pathology.

[4]  K. Hoang-Xuan,et al.  Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  D. Steindler,et al.  Human cortical glial tumors contain neural stem‐like cells expressing astroglial and neuronal markers in vitro , 2002, Glia.

[6]  Ming Li,et al.  Associations between SOX2 and miR-200b expression with the clinicopathological characteristics and prognosis of patients with glioma. , 2015, Experimental and therapeutic medicine.

[7]  K. Zilles,et al.  A link between the systems: functional differentiation and integration within the human insula revealed by meta-analysis , 2010, Brain Structure and Function.

[8]  O. Chinot,et al.  Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis , 2010, Acta Neuropathologica.

[9]  O. Chinot,et al.  Deletions of Chromosomes 1p and 19q are Detectable on Frozen Smears of Gliomas by FISH: Usefulness for Stereotactic Biopsies , 2004, Journal of Neuro-Oncology.

[10]  A. Marchetti,et al.  IDH1 mutations at residue p.R132 (IDH1R132) occur frequently in high‐grade gliomas but not in other solid tumors , 2009, Human mutation.

[11]  Daniel H. Geschwind,et al.  Cancerous stem cells can arise from pediatric brain tumors , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[12]  M. Wolter,et al.  A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. , 2010, Brain : a journal of neurology.

[13]  Ryder Gwinn,et al.  Embryological development of the human insula and its implications for the spread and resection of insular gliomas. , 2009, Neurosurgical focus.

[14]  Pieter Wesseling,et al.  IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group , 2010, Clinical Cancer Research.

[15]  Ugo Orfanelli,et al.  Isolation and Characterization of Tumorigenic, Stem-like Neural Precursors from Human Glioblastoma , 2004, Cancer Research.

[16]  O. Chinot,et al.  Molecular genetics of adult grade II gliomas: towards a comprehensive tumor classification system , 2012, Journal of Neuro-Oncology.

[17]  Andrey Korshunov,et al.  Analysis of the IDH1 codon 132 mutation in brain tumors , 2008, Acta Neuropathologica.

[18]  T. Kiehl,et al.  Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas. , 2014, Neuro-oncology.

[19]  E. Jauniaux,et al.  Regional specification of rodent and human neurospheres. , 2002, Brain research. Developmental brain research.

[20]  J. Boockvar,et al.  Glioblastoma multiforme stem-like cells and hypoxia: the novel role of HAF. , 2011, Neurosurgery.

[21]  Alexander R. Pico,et al.  Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. , 2015, The New England journal of medicine.

[22]  Satoru Miyano,et al.  Mutational landscape and clonal architecture in grade II and III gliomas , 2015, Nature Genetics.

[23]  C. Eberhart,et al.  DNMT-dependent suppression of microRNA regulates the induction of GBM tumor-propagating phenotype by Oct4 and Sox2 , 2014, Oncogene.

[24]  Christian Mawrin,et al.  Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas , 2009, Acta Neuropathologica.

[25]  K. Amunts,et al.  Receptor mapping: architecture of the human cerebral cortex , 2009, Current opinion in neurology.

[26]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[27]  Katrin Amunts,et al.  Cytoarchitecture and probabilistic maps of the human posterior insular cortex. , 2010, Cerebral cortex.

[28]  O. Chinot,et al.  IDH mutation status impact on in vivo hypoxia biomarkers expression: new insights from a clinical, nuclear imaging and immunohistochemical study in 33 glioma patients , 2011, Journal of Neuro-Oncology.

[29]  E. Goldwasser,et al.  A new transacting factor that modulates hypoxia-induced expression of the erythropoietin gene. , 2000, Blood.

[30]  G. Powis,et al.  Passing the baton: the HIF switch. , 2012, Trends in biochemical sciences.

[31]  F. Ducray,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[32]  R. Verhaak,et al.  Transformation by the R Enantiomer of 2-Hydroxyglutarate Linked to EglN Activation , 2012, Nature.

[33]  David T. W. Jones,et al.  ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma , 2014, Acta Neuropathologica.

[34]  F. Ducray,et al.  Cortical and Subventricular Zone Glioblastoma-Derived Stem-Like Cells Display Different Molecular Profiles and Differential In Vitro and In Vivo Properties , 2012, Annals of Surgical Oncology.

[35]  Cynthia Hawkins,et al.  Identification of a cancer stem cell in human brain tumors. , 2003, Cancer research.

[36]  Changxiang Yan,et al.  Prognostic significance of IDH mutation in adult low-grade gliomas: a meta-analysis , 2013, Journal of Neuro-Oncology.

[37]  G. Powis,et al.  Hypoxia-Associated Factor, a Novel E3-Ubiquitin Ligase, Binds and Ubiquitinates Hypoxia-Inducible Factor 1α, Leading to Its Oxygen-Independent Degradation , 2008, Molecular and Cellular Biology.